drugset / Trial / NCT03979365

Envarsus XR Compared to Immediate Release Tacrolimus

NCT03979365 ↗

Phase 4 Completed 261 enrolled Mayo Clinic Veloxis Pharmaceuticals · collab
RandomizedParallel-groupOpen-labelSupportive care

Summary

The purpose of this study is to compare once-daily tacrolimus extended-release (Envarsus XR®) to twice-daily immediate release tacrolimus to find out if people taking tacrolimus extended release (Envarsus XR®) report fewer side effects, increased medication compliance and higher scores on quality of life assessments compared to people taking twice daily tacrolimus immediate release.

Timeline

Start
2019-07-18
Primary completion
2022-03-29
Completion
2022-03-29

Drugs

EvaluationDrugModalityDoseRoute
Comparator Tacrolimus Small molecule — Oral